Gentian Diagnostics ASA

Regulatory Filings • Mar 19, 2025

Gentian Diagnostics Receives Notice of Allowance for NT-proBNP Assay Patent in Japan

Gentian Diagnostics Receives Notice of Allowance for NT-proBNP Assay Patent in Japan

Moss, 19 March 2025

Gentian Diagnostics, a fast growing developer and manufacturer of diagnostic tests, is pleased to announce that the Japanese Patent Office has issued a notice of allowance for the company’s patent application related to its NT-proBNP diagnostic assay. This upcoming patent grant further strengthens Gentian’s intellectual property portfolio and enhances its position in the heart failure diagnostics market.

Japan is the third-largest in vitro diagnostics (IVD) market for laboratory diagnostics related to heart failure testing, following the United States and China. Securing intellectual property protection in this key market provides Gentian with significant commercial opportunities and reinforces the company’s strategic position in heart failure diagnostics.

The patent protects Gentian’s innovative approach to NT-proBNP measurement using turbidimetric immunoassay technology. This development builds upon Gentian’s existing patents, including its granted U.S. patent, reinforcing the company’s competitive advantage and providing strong protection against potential market entrants.

“This patent represents a significant milestone for Gentian and further validates our commitment to advancing high-precision diagnostic solutions,” said Torsten Knüttel, VP R&D of Gentian Diagnostics. “Securing this protection in Japan, one of the world’s leading healthcare markets, strengthens our global market position and provides new opportunities for commercialization.”

About Gentian Diagnostics

Gentian Diagnostics (OSE: GENT), develops and manufactures high-quality, in vitro diagnostic reagents. Gentian’s expertise and focus lies within immunoassays, specifically infection, inflammation, kidney disease and heart failure. By converting existing and clinically relevant biomarkers to the most efficient automated, high-throughput analyzers, the company contributes to saving costs and protecting life. Gentian is headquartered in Moss, Norway, serving the global human and veterinary diagnostics markets through sales and representative offices in Sweden, USA, and China. For more information, please visit www.gentian.com.

IR Contact:

Njaal Kind, CFO

njaal.kind@gentian.no

+47 919 06 525 (mobile)